<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085836</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-438_114</org_study_id>
    <secondary_id>U1111-1191-6949</secondary_id>
    <secondary_id>CTR20170137</secondary_id>
    <nct_id>NCT03085836</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants</brief_title>
  <official_title>An Open-Label, Single-center, Parallel, Phase 1 Study to Determine the Pharmacokinetics of Single- and Multiple- Oral Doses of TAK-438 10 mg and 20 mg in Healthy Adult Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics (PK) of TAK-438 in healthy
      adult Chinese participants after both single and multiple dose administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-438. TAK-438 is being tested in healthy
      participants in order to evaluate the PK of single and multiple oral dose.

      The study will enroll approximately 36 healthy participants. Participants will be assigned to
      one of the three treatment groups:

        -  TAK-438 10 mg tablet once daily

        -  TAK-438 20 mg tablet once daily

        -  TAK-438 20 mg tablet twice daily All participants will be asked to take TAK-438 tablet
           at the same time on Day 1 and Days 3-9.

      This single-centre trial will be conducted in China. The overall time to participate in this
      study is 18 days. Participants will remain confined to the clinic from Day 1 up to Day 11 and
      will be followed-up by telephone or visit on Day 18.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Actual">August 17, 2017</completion_date>
  <primary_completion_date type="Actual">August 17, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</measure>
    <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</measure>
    <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</measure>
    <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Tau Over the Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</measure>
    <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2z: Terminal Disposition Half-life for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</measure>
    <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss: Maximum Observed Plasma Concentration, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</measure>
    <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax, ss: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</measure>
    <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss: Area Under the Plasma Concentration-time Curve During a Dosing Interval, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</measure>
    <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aet: Total Amount of Drug Excreted in Urine From Time 0 to Time T for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</measure>
    <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fe,t: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</measure>
    <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLr: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</measure>
    <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</measure>
    <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fe,τ: Fraction of Administered Dose of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</measure>
    <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</measure>
    <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>TAK-438 10 milligram (mg) Once Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-438 10 mg, tablets, orally, once daily on Days 1, 3-9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-438 20 mg Once Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-438 20 mg, tablets, orally, once daily on Days 1, 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-438 20 mg Twice Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-438 20 mg, tablets, orally, once on Day 1 and twice daily on Days 3-9. Participants were asked to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-438</intervention_name>
    <description>TAK-438 tablets.</description>
    <arm_group_label>TAK-438 10 milligram (mg) Once Daily</arm_group_label>
    <arm_group_label>TAK-438 20 mg Once Daily</arm_group_label>
    <arm_group_label>TAK-438 20 mg Twice Daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a healthy adult male or female Chinese participant.

          2. Is aged 18 to 45 years, inclusive, at the time of signing the informed consent form.

          3. Weighs at least 50 kilogram (kg) and has a body mass index (BMI) between 19 and 26
             kilogram per square meter (kg/m^2), inclusive at Screening (Check-In Day -1).

          4. Is willing to abstain from caffeine and alcohol from 72 hours before first dose (Day
             1) until the Follow-up Visit on Day 18.

          5. Is willing to abstain from strenuous exercise from 72 hours before first dose (Day 1)
             until the Follow-up Visit on Day 18.

          6. Is willing to provide a sample for pharmacogenetic analysis (for cytochrome [CYP2C19]
             genotyping).

        Exclusion Criteria:

          1. Has uncontrolled, clinically significant cardiovascular disease or other abnormality,
             which may impact the ability of the participant to participate or potentially confound
             the study results.

          2. Is lactose intolerant or has a known hypersensitivity to any component of the
             formulation of TAK-438.

          3. Has poor peripheral venous access.

          4. Has donated or lost 400 milliliter (mL) or more of his or her blood volume (including
             plasmapheresis), or had a transfusion of any blood product within 90 days prior to Day
             1; or participant has donated or lost more than 200 mL or more of his or her blood in
             the last 28 days.

          5. Has a history of symptomatic gastroesophageal reflux disease (GERD), Erosive
             Esophagitis, duodenal ulcer (DU), gastric ulcer (GU), dyspepsia, Barrett's Esophagus,
             or Zollinger-Ellison (ZE) syndrome or has current or recent (within 6 months)
             gastrointestinal disease that would be expected to influence the absorption of drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <results_first_submitted>August 15, 2018</results_first_submitted>
  <results_first_submitted_qc>August 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2019</results_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03085836/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03085836/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in China from 19 April 2017 to 17 August 2017.</recruitment_details>
      <pre_assignment_details>Healthy Chinese participants were enrolled in this study to receive treatment in one of the 3 treatment groups: TAK-438 10 milligram (mg) once daily or TAK-438 20 mg once daily or TAK-438-20 mg twice daily.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAK-438 10 mg Once Daily</title>
          <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
        </group>
        <group group_id="P2">
          <title>TAK-438 20 mg Once Daily</title>
          <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
        </group>
        <group group_id="P3">
          <title>TAK-438 20 mg Twice Daily</title>
          <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The pharmacokinetic (PK) set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
      <group_list>
        <group group_id="B1">
          <title>TAK-438 10 mg Once Daily</title>
          <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
        </group>
        <group group_id="B2">
          <title>TAK-438 20 mg Once Daily</title>
          <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
        </group>
        <group group_id="B3">
          <title>TAK-438 20 mg Twice Daily</title>
          <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.2" spread="2.95"/>
                    <measurement group_id="B2" value="23.9" spread="3.99"/>
                    <measurement group_id="B3" value="27.2" spread="4.83"/>
                    <measurement group_id="B4" value="25.4" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.35" spread="8.426"/>
                    <measurement group_id="B2" value="169.59" spread="7.672"/>
                    <measurement group_id="B3" value="164.31" spread="9.377"/>
                    <measurement group_id="B4" value="166.81" spread="8.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.63" spread="7.601"/>
                    <measurement group_id="B2" value="66.05" spread="8.501"/>
                    <measurement group_id="B3" value="61.66" spread="6.449"/>
                    <measurement group_id="B4" value="63.47" spread="7.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.63" spread="2.086"/>
                    <measurement group_id="B2" value="22.89" spread="1.711"/>
                    <measurement group_id="B3" value="22.88" spread="2.110"/>
                    <measurement group_id="B4" value="22.79" spread="1.918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking classification</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Never smoked</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol consumption</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Never drank</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine consumption</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Had no caffeine consumption</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cytochrome P450 2C19 (CYP2C19) Genotype</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>*1/*1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>*1/*2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>*1/*3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>*2/*2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>*2/*3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>*3/*3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
        <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.148" spread="2.9972"/>
                    <measurement group_id="O2" value="18.18" spread="4.4973"/>
                    <measurement group_id="O3" value="25.23" spread="10.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.32" spread="8.6143"/>
                    <measurement group_id="O2" value="67.95" spread="23.388"/>
                    <measurement group_id="O3" value="59.02" spread="18.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.840" spread="1.0442"/>
                    <measurement group_id="O2" value="5.155" spread="2.7868"/>
                    <measurement group_id="O3" value="4.879" spread="2.2426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.42" spread="3.7788"/>
                    <measurement group_id="O2" value="25.63" spread="7.8650"/>
                    <measurement group_id="O3" value="25.67" spread="5.9219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.29" spread="5.0563"/>
                    <measurement group_id="O2" value="60.67" spread="16.499"/>
                    <measurement group_id="O3" value="42.28" spread="9.1174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
        <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.750" lower_limit="1.00" upper_limit="4.02"/>
                    <measurement group_id="O2" value="2.000" lower_limit="0.750" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.500" lower_limit="0.750" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="0.750" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.500" lower_limit="0.750" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.000" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.010" lower_limit="3.00" upper_limit="10.0"/>
                    <measurement group_id="O2" value="6.000" lower_limit="3.00" upper_limit="10.0"/>
                    <measurement group_id="O3" value="10.00" lower_limit="3.00" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.750" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="2.000" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.000" lower_limit="1.50" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.500" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.000" lower_limit="1.50" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
        <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>hour*nanogram per milliliter (h*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.38" spread="29.197"/>
                    <measurement group_id="O2" value="188.1" spread="43.066"/>
                    <measurement group_id="O3" value="226.8" spread="67.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305.7" spread="88.227"/>
                    <measurement group_id="O2" value="617.2" spread="213.56"/>
                    <measurement group_id="O3" value="578.7" spread="144.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.97" spread="22.843"/>
                    <measurement group_id="O2" value="106.3" spread="74.306"/>
                    <measurement group_id="O3" value="117.8" spread="41.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.83" spread="34.769"/>
                    <measurement group_id="O2" value="178.7" spread="64.779"/>
                    <measurement group_id="O3" value="193.7" spread="56.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.5" spread="44.602"/>
                    <measurement group_id="O2" value="307.5" spread="89.884"/>
                    <measurement group_id="O3" value="240.8" spread="82.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Tau Over the Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
        <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Tau Over the Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.91" spread="24.835"/>
                    <measurement group_id="O2" value="168.6" spread="37.455"/>
                    <measurement group_id="O3" value="154.8" spread="38.920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.4" spread="77.758"/>
                    <measurement group_id="O2" value="528.8" spread="182.62"/>
                    <measurement group_id="O3" value="344.1" spread="91.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.77" spread="18.646"/>
                    <measurement group_id="O2" value="79.07" spread="56.206"/>
                    <measurement group_id="O3" value="41.55" spread="19.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.98" spread="31.136"/>
                    <measurement group_id="O2" value="169.2" spread="59.474"/>
                    <measurement group_id="O3" value="149.1" spread="36.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.1" spread="43.648"/>
                    <measurement group_id="O2" value="296.0" spread="86.359"/>
                    <measurement group_id="O3" value="192.8" spread="57.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2z: Terminal Disposition Half-life for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
        <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations. PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2z: Terminal Disposition Half-life for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations. PK analysis population where data at specified time points were available.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.879" spread="1.2352"/>
                    <measurement group_id="O2" value="6.996" spread="1.0110"/>
                    <measurement group_id="O3" value="7.116" spread="0.71638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.82" spread="4.0923"/>
                    <measurement group_id="O2" value="8.256" spread="1.2964"/>
                    <measurement group_id="O3" value="8.385" spread="0.73316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.52" spread="4.3311"/>
                    <measurement group_id="O2" value="10.37" spread="2.9973"/>
                    <measurement group_id="O3" value="12.29" spread="4.0538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.695" spread="1.3786"/>
                    <measurement group_id="O2" value="6.335" spread="1.1833"/>
                    <measurement group_id="O3" value="6.791" spread="0.89228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.753" spread="2.4430"/>
                    <measurement group_id="O2" value="5.698" spread="1.2625"/>
                    <measurement group_id="O3" value="5.521" spread="2.2225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax,ss: Maximum Observed Plasma Concentration, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
        <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss: Maximum Observed Plasma Concentration, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.01" spread="3.4863"/>
                    <measurement group_id="O2" value="23.43" spread="6.1433"/>
                    <measurement group_id="O3" value="37.88" spread="10.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.39" spread="9.6528"/>
                    <measurement group_id="O2" value="79.85" spread="22.119"/>
                    <measurement group_id="O3" value="59.55" spread="15.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.558" spread="1.4983"/>
                    <measurement group_id="O2" value="6.554" spread="2.6078"/>
                    <measurement group_id="O3" value="9.174" spread="2.8376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.62" spread="4.1919"/>
                    <measurement group_id="O2" value="30.15" spread="7.3228"/>
                    <measurement group_id="O3" value="33.01" spread="6.1638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.33" spread="3.6619"/>
                    <measurement group_id="O2" value="54.08" spread="13.927"/>
                    <measurement group_id="O3" value="39.74" spread="7.1405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax, ss: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
        <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax, ss: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="0.750" upper_limit="3.02"/>
                    <measurement group_id="O2" value="2.000" lower_limit="0.750" upper_limit="3.00"/>
                    <measurement group_id="O3" value="3.000" lower_limit="0.750" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="0.750" upper_limit="2.02"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.750" upper_limit="2.00"/>
                    <measurement group_id="O3" value="2.500" lower_limit="1.00" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3.000" lower_limit="3.00" upper_limit="10.0"/>
                    <measurement group_id="O3" value="3.500" lower_limit="0.00" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.750" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.000" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O3" value="3.000" lower_limit="1.50" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="1.500" lower_limit="1.50" upper_limit="2.00"/>
                    <measurement group_id="O3" value="3.000" lower_limit="1.50" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCτ,ss: Area Under the Plasma Concentration-time Curve During a Dosing Interval, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
        <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations. PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ,ss: Area Under the Plasma Concentration-time Curve During a Dosing Interval, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations. PK analysis population where data at specified time points were available.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.90" spread="28.053"/>
                    <measurement group_id="O2" value="212.7" spread="57.214"/>
                    <measurement group_id="O3" value="273.4" spread="71.830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285.5" spread="77.884"/>
                    <measurement group_id="O2" value="581.1" spread="198.14"/>
                    <measurement group_id="O3" value="435.3" spread="92.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.31" spread="24.298"/>
                    <measurement group_id="O2" value="105.5" spread="51.688"/>
                    <measurement group_id="O3" value="100.4" spread="27.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.94" spread="29.719"/>
                    <measurement group_id="O2" value="194.6" spread="53.749"/>
                    <measurement group_id="O3" value="222.6" spread="49.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.1" spread="37.489"/>
                    <measurement group_id="O2" value="256.1" spread="62.786"/>
                    <measurement group_id="O3" value="225.7" spread="52.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aet: Total Amount of Drug Excreted in Urine From Time 0 to Time T for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
        <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>Aet: Total Amount of Drug Excreted in Urine From Time 0 to Time T for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>microgram (mcg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448.5" spread="159.06"/>
                    <measurement group_id="O2" value="890.3" spread="243.24"/>
                    <measurement group_id="O3" value="1478" spread="405.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.6" spread="79.813"/>
                    <measurement group_id="O2" value="253.1" spread="118.69"/>
                    <measurement group_id="O3" value="211.2" spread="124.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.5120" spread="1.6191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.4" spread="61.587"/>
                    <measurement group_id="O2" value="422.1" spread="143.24"/>
                    <measurement group_id="O3" value="387.1" spread="142.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fe,t: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
        <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>Fe,t: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>percentage of drug</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.485" spread="1.5906"/>
                    <measurement group_id="O2" value="4.448" spread="1.2093"/>
                    <measurement group_id="O3" value="7.399" spread="2.0335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.760" spread="0.79678"/>
                    <measurement group_id="O2" value="1.262" spread="0.59122"/>
                    <measurement group_id="O3" value="1.053" spread="0.61992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.002460" spread="0.0077792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.609" spread="0.48258"/>
                    <measurement group_id="O2" value="1.650" spread="0.56108"/>
                    <measurement group_id="O3" value="1.513" spread="0.55536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CLr: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
        <time_frame>Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations. PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>CLr: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations. PK analysis population where data at specified time points were available.</population>
          <units>liter per hour (L/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.443" spread="1.0398"/>
                    <measurement group_id="O2" value="4.922" spread="1.4362"/>
                    <measurement group_id="O3" value="6.733" spread="1.3109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6235" spread="0.16437"/>
                    <measurement group_id="O2" value="0.4465" spread="0.24193"/>
                    <measurement group_id="O3" value="0.3753" spread="0.19679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.001820" spread="0.0057553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.748" spread="0.65948"/>
                    <measurement group_id="O2" value="1.527" spread="0.77444"/>
                    <measurement group_id="O3" value="1.707" spread="0.47416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
        <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>mcg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437.7" spread="121.93"/>
                    <measurement group_id="O2" value="859.9" spread="155.66"/>
                    <measurement group_id="O3" value="1327" spread="274.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224.3" spread="79.531"/>
                    <measurement group_id="O2" value="354.1" spread="165.88"/>
                    <measurement group_id="O3" value="340.9" spread="181.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.2" spread="52.172"/>
                    <measurement group_id="O2" value="390.7" spread="99.477"/>
                    <measurement group_id="O3" value="446.4" spread="139.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fe,τ: Fraction of Administered Dose of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
        <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>Fe,τ: Fraction of Administered Dose of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.</population>
          <units>percentage of drug</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.377" spread="1.2193"/>
                    <measurement group_id="O2" value="4.299" spread="0.77678"/>
                    <measurement group_id="O3" value="6.634" spread="1.3737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.236" spread="0.79323"/>
                    <measurement group_id="O2" value="1.765" spread="0.82755"/>
                    <measurement group_id="O3" value="1.700" spread="0.90664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.605" spread="0.40853"/>
                    <measurement group_id="O2" value="1.528" spread="0.38946"/>
                    <measurement group_id="O3" value="1.748" spread="0.54499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CLR: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
        <time_frame>Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose</time_frame>
        <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations. PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-438 10 mg Once Daily</title>
            <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O2">
            <title>TAK-438 20 mg Once Daily</title>
            <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
          </group>
          <group group_id="O3">
            <title>TAK-438 20 mg Twice Daily</title>
            <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>CLR: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9</title>
          <population>The PK set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations. PK analysis population where data at specified time points were available.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-438F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.848" spread="1.2372"/>
                    <measurement group_id="O2" value="4.251" spread="1.1565"/>
                    <measurement group_id="O3" value="4.977" spread="0.71952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8126" spread="0.26393"/>
                    <measurement group_id="O2" value="0.6207" spread="0.22632"/>
                    <measurement group_id="O3" value="0.7943" spread="0.39001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000"/>
                    <measurement group_id="O3" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-IV-Sul</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.931" spread="0.79907"/>
                    <measurement group_id="O2" value="1.614" spread="0.58643"/>
                    <measurement group_id="O3" value="2.067" spread="0.70761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to follow-up (Day 1 up to Day 18)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAK-438 10 mg Once Daily</title>
          <description>TAK-438 10 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
        </group>
        <group group_id="E2">
          <title>TAK-438 20 mg Once Daily</title>
          <description>TAK-438 20 mg, tablet, orally, once daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.</description>
        </group>
        <group group_id="E3">
          <title>TAK-438 20 mg Twice Daily</title>
          <description>TAK-438 20 mg, tablet, orally, twice daily on Days 1, 3 to 9. Participants were required to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

